Education
About Us
Working with TipRanks
Follow Us
Steven Basta Insider Profile
4 Followers
Steven Basta, Director at KalVista Pharmaceuticals, holds 113.79K shares in Phathom Pharmaceuticals (Ticker: PHAT), holds 25.00 shares in Viveve Medical (Ticker: VIVE), holds 536.54K shares in VYNE Therapeutics (Ticker: VYNE).
Steven Basta has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Steven Basta holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Steven Basta
Steven Basta's Trading History
KalVista Pharmaceuticals
Nov 22, 2016
Director
Uninformative Buy
―
$0.00
VYNE Therapeutics
Apr 07, 2020
Director
Uninformative Buy
―
$304.75K
Viveve Medical
Dec 17, 2021
Director
Uninformative Sell
39.48
―
Phathom Pharmaceuticals
Dec 19, 2025
President & CEO, Director
Uninformative Buy
―
$1.96M
List of latest transactions for each holding click on a transaction to see Steven Basta's performance on stock
You May Also Like
Steven Basta insider profile FAQ
What is the percentage of profitable transactions made by Steven Basta?
The percentage of profitable transactions made by Steven Basta is ―.
What is the average return per transaction made by Steven Basta?
The average return per transaction made by Steven Basta is ―.
What stocks does Steven Basta hold?
Steven Basta holds: KALV, VYNE, VIVE, PHAT stocks.
What was Steven Basta’s latest transaction?
Steven Basta latest transaction was an Uninformative Buy of ―.
What was Steven Basta's most profitable transaction?
Steven Basta’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Steven Basta's role in KalVista Pharmaceuticals?
Steven Basta's role in KalVista Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.